Johannes Oldenburg Selected Research

Heparin (Liquaemin)

6/2021	Diagnosis and Management of Vaccine-Related Thrombosis following AstraZeneca COVID-19 Vaccination: Guidance Statement from the GTH.
1/2017	A rare case of unprovoked venous thromboembolism manifestation in a young patient with antithrombin Type IIB deficiency combined with inferior vena cava anomaly from Lithuania.
1/2015	Determination of plasma heparin level improves identification of systemic mast cell activation disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Johannes Oldenburg Research Topics

Disease

110	Hemophilia A (Haemophilia) 04/2024 - 06/2002
81	Hemorrhage 04/2024 - 11/2002
18	Thrombosis (Thrombus) 02/2024 - 03/2006
13	Hemophilia B (Haemophilia B) 01/2024 - 09/2003
9	Thrombophilia 02/2024 - 08/2012
7	Thrombotic Microangiopathies 12/2023 - 01/2017
7	COVID-19 11/2023 - 03/2021
7	Infections 03/2021 - 01/2009
6	Venous Thromboembolism 01/2024 - 01/2005
6	Type 3 von Willebrand Disease 01/2023 - 11/2019
6	von Willebrand Diseases (von Willebrand's Disease) 01/2022 - 07/2004
5	1 Combined Deficiency Of Vitamin K-Dependent Clotting Factors 01/2022 - 08/2004
5	Type 2 Combined Deficiency Of Vitamin K-Dependent Clotting Factors 08/2015 - 02/2004
5	Coumarin Resistance 10/2013 - 02/2004
4	Activated Protein C Resistance (APC Resistance) 01/2024 - 01/2014
4	Neoplasms (Cancer) 01/2024 - 01/2019
4	Factor XIII Deficiency 10/2023 - 06/2010
4	Venous Thrombosis (Deep-Vein Thrombosis) 01/2022 - 01/2005
3	Wounds and Injuries (Trauma) 01/2022 - 01/2014
3	Joint Diseases (Joint Disease) 11/2021 - 03/2015
3	Thrombocytopenia (Thrombopenia) 10/2021 - 10/2016
3	Metrorrhagia (Spotting) 05/2021 - 01/2017
3	Hypersensitivity (Allergy) 06/2018 - 02/2008
3	Autoimmune Diseases (Autoimmune Disease) 01/2018 - 04/2006
2	Hemolysis 04/2024 - 01/2021
2	Injection Site Reaction 12/2023 - 01/2017
2	Body Weight (Weight, Body) 01/2023 - 01/2018
2	Thrombotic Thrombocytopenic Purpura 09/2022 - 01/2022
2	Mast Cell Activation Disorders (Mast-Cell Disease) 08/2021 - 01/2015
2	Inborn Genetic Diseases (Disease, Hereditary) 01/2021 - 06/2005
2	Vitamin K Deficiency 01/2021 - 10/2014
2	Thromboembolism 01/2017 - 08/2015
2	Hydatidiform Mole (Molar Pregnancy) 01/2015 - 10/2014

Drug/Important Bio-Agent (IBA)

77	Factor VIII (Coagulation Factor VIII)IBA 04/2024 - 06/2002
25	Blood Coagulation Factors (Coagulation Factor)IBA 12/2022 - 11/2002
23	emicizumabIBA 01/2024 - 01/2017
18	Vitamin K FDA Link 04/2022 - 02/2004
16	Proteins (Proteins, Gene)FDA Link 03/2024 - 01/2004
16	Thrombin FDA Link 02/2024 - 05/2012
15	AntibodiesIBA 03/2024 - 04/2006
14	AnticoagulantsIBA 02/2024 - 02/2004
13	von Willebrand FactorIBA 01/2023 - 10/2012
11	Protein CIBA 02/2024 - 11/2002
11	Factor IX (Coagulation Factor IX)FDA LinkGeneric 01/2024 - 09/2003
10	Prothrombin (Factor II)IBA 01/2024 - 01/2017
8	Factor XIII (Coagulation Factor XIII)IBA 10/2023 - 06/2010
6	Heme (Haem)IBA 04/2024 - 01/2019
6	AutoantibodiesIBA 12/2023 - 04/2009
5	recombinant factor VIII N8IBA 02/2024 - 01/2017
5	Hemostatics (Antihemorrhagics)IBA 01/2024 - 01/2016
5	glutamyl carboxylase (gamma-glutamyl carboxylase)IBA 01/2022 - 08/2004
5	AntigensIBA 01/2020 - 01/2004
5	DNA (Deoxyribonucleic Acid)IBA 01/2019 - 09/2011
4	Immunoglobulin G (IgG)IBA 03/2024 - 11/2008
4	VaccinesIBA 09/2022 - 06/2021
4	Antiviral Agents (Antivirals)IBA 01/2018 - 01/2009
4	AntithrombinsIBA 01/2018 - 08/2011
4	coumarinIBA 11/2008 - 02/2004
3	Fibrinogen (Factor I)FDA Link 04/2024 - 01/2017
3	Immunoglobulins (Immunoglobulin)IBA 03/2024 - 12/2009
3	Factor VIIa (Activated Factor VII)IBA 02/2024 - 01/2022
3	Biomarkers (Surrogate Marker)IBA 02/2024 - 10/2016
3	AlbuminsIBA 01/2024 - 01/2016
3	MicroRNAs (MicroRNA)IBA 01/2024 - 01/2020
3	6-pyruvoyltetrahydropterin synthase (PTPS)IBA 10/2023 - 01/2019
3	simoctocog alfa (Nuwiq)IBA 10/2023 - 01/2019
3	factor IX Fc fusion proteinIBA 07/2023 - 01/2017
3	IsoantibodiesIBA 01/2023 - 02/2015
3	apixabanIBA 05/2022 - 01/2020
3	RivaroxabanIBA 05/2022 - 01/2020
3	Messenger RNA (mRNA)IBA 01/2022 - 04/2006
3	Heparin (Liquaemin)FDA LinkGeneric 06/2021 - 01/2015
3	Warfarin (Coumadin)FDA LinkGeneric 01/2021 - 02/2004
3	Platelet Membrane GlycoproteinsIBA 01/2020 - 09/2011
3	nonacog beta pegolIBA 11/2018 - 12/2014
3	Protein SIBA 01/2017 - 11/2002
3	Vitamin K Epoxide ReductasesIBA 10/2014 - 09/2006
3	N- methyl- N- (1- phenylethyl)- 2- propynylamineIBA 02/2014 - 12/2009
3	EnzymesIBA 10/2013 - 06/2006
3	Interleukin-10 (Interleukin 10)IBA 04/2010 - 04/2006
2	Valoctocogene RoxaparvovecIBA 04/2024 - 01/2023
2	Factor VII (Proconvertin)IBA 02/2024 - 01/2012
2	recombinant FVIIa (rFVIIa)FDA Link 02/2024 - 01/2022
2	Recombinant Fusion ProteinsIBA 01/2024 - 01/2016
2	Vitamin D FDA LinkGeneric 06/2023 - 10/2006
2	thiamine triphosphorate (TTP)IBA 09/2022 - 01/2022
2	RNA (Ribonucleic Acid)IBA 03/2022 - 05/2021
2	Matrix Gla ProteinIBA 01/2022 - 10/2014
2	COVID-19 VaccinesIBA 01/2022 - 06/2021
2	concizumabIBA 01/2022 - 11/2019
2	Monoclonal AntibodiesIBA 01/2021 - 12/2019
2	factor VIII-Fc fusion proteinIBA 05/2020 - 01/2016
2	Antiphospholipid AntibodiesIBA 01/2020 - 05/2012
2	Factor IXa (Coagulation Factor IXa)IBA 12/2019 - 01/2017
2	Interleukin-6 (Interleukin 6)IBA 12/2018 - 01/2012

Therapy/Procedure

36	Therapeutics 04/2024 - 09/2003
3	Transcatheter Aortic Valve Replacement 10/2021 - 10/2016
3	Injections 01/2019 - 01/2017
2	Conservative Treatment 11/2021 - 03/2017
2	Immunotherapy 01/2021 - 01/2021